CN105596358B - Compound capsule - Google Patents
Compound capsule Download PDFInfo
- Publication number
- CN105596358B CN105596358B CN201610060285.7A CN201610060285A CN105596358B CN 105596358 B CN105596358 B CN 105596358B CN 201610060285 A CN201610060285 A CN 201610060285A CN 105596358 B CN105596358 B CN 105596358B
- Authority
- CN
- China
- Prior art keywords
- capsule
- vitamin
- filler
- grain
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 261
- 150000001875 compounds Chemical class 0.000 title description 5
- 239000000945 filler Substances 0.000 claims abstract description 48
- 239000000843 powder Substances 0.000 claims abstract description 42
- 229920000159 gelatin Polymers 0.000 claims abstract description 24
- 235000019322 gelatine Nutrition 0.000 claims abstract description 24
- 108010010803 Gelatin Proteins 0.000 claims abstract description 23
- 239000008273 gelatin Substances 0.000 claims abstract description 23
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 21
- 239000011149 active material Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims description 71
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 45
- 229920002472 Starch Polymers 0.000 claims description 39
- 239000008107 starch Substances 0.000 claims description 39
- 235000019698 starch Nutrition 0.000 claims description 39
- 239000011812 mixed powder Substances 0.000 claims description 33
- 229930182817 methionine Natural products 0.000 claims description 32
- 235000006109 methionine Nutrition 0.000 claims description 32
- 229960004452 methionine Drugs 0.000 claims description 32
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 31
- 235000012239 silicon dioxide Nutrition 0.000 claims description 31
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 24
- 239000007902 hard capsule Substances 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 14
- 238000007789 sealing Methods 0.000 claims description 14
- 239000011343 solid material Substances 0.000 claims description 14
- 239000004470 DL Methionine Substances 0.000 claims description 12
- 229930195722 L-methionine Natural products 0.000 claims description 12
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 5
- 238000013459 approach Methods 0.000 claims description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 20
- 238000011282 treatment Methods 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001684 chronic effect Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 7
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 230000004071 biological effect Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000012549 training Methods 0.000 abstract description 4
- 230000008030 elimination Effects 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 68
- 229940024606 amino acid Drugs 0.000 description 67
- 235000001014 amino acid Nutrition 0.000 description 67
- 150000001413 amino acids Chemical class 0.000 description 62
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 60
- 238000002360 preparation method Methods 0.000 description 55
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 52
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 52
- 238000012360 testing method Methods 0.000 description 42
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 38
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 37
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 34
- 229930003268 Vitamin C Natural products 0.000 description 34
- 235000019154 vitamin C Nutrition 0.000 description 34
- 239000011718 vitamin C Substances 0.000 description 34
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 33
- 229960003495 thiamine Drugs 0.000 description 33
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 33
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 31
- 229960002061 ergocalciferol Drugs 0.000 description 31
- 239000011782 vitamin Substances 0.000 description 31
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 31
- 235000001892 vitamin D2 Nutrition 0.000 description 31
- 239000011653 vitamin D2 Substances 0.000 description 31
- 229930003427 Vitamin E Natural products 0.000 description 30
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 30
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- 229940046009 vitamin E Drugs 0.000 description 30
- 235000019165 vitamin E Nutrition 0.000 description 30
- 239000011709 vitamin E Substances 0.000 description 30
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 29
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 29
- 229940088594 vitamin Drugs 0.000 description 29
- 235000019155 vitamin A Nutrition 0.000 description 29
- 239000011719 vitamin A Substances 0.000 description 29
- 229940045997 vitamin a Drugs 0.000 description 29
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 27
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 27
- 229930003471 Vitamin B2 Natural products 0.000 description 27
- 229960002477 riboflavin Drugs 0.000 description 27
- 235000019164 vitamin B2 Nutrition 0.000 description 27
- 239000011716 vitamin B2 Substances 0.000 description 27
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 26
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 26
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 26
- 229960000304 folic acid Drugs 0.000 description 26
- 235000019152 folic acid Nutrition 0.000 description 26
- 239000011724 folic acid Substances 0.000 description 26
- 229960003966 nicotinamide Drugs 0.000 description 26
- 235000005152 nicotinamide Nutrition 0.000 description 26
- 239000011570 nicotinamide Substances 0.000 description 26
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 229930003231 vitamin Natural products 0.000 description 26
- 235000013343 vitamin Nutrition 0.000 description 26
- 235000019158 vitamin B6 Nutrition 0.000 description 26
- 239000011726 vitamin B6 Substances 0.000 description 26
- 229940011671 vitamin b6 Drugs 0.000 description 26
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 25
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 25
- 229960004295 valine Drugs 0.000 description 25
- 239000004474 valine Substances 0.000 description 25
- 235000014393 valine Nutrition 0.000 description 25
- 239000004473 Threonine Substances 0.000 description 24
- 229960002898 threonine Drugs 0.000 description 24
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 23
- 229960002079 calcium pantothenate Drugs 0.000 description 23
- 229960005190 phenylalanine Drugs 0.000 description 23
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 22
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 22
- 229930003451 Vitamin B1 Natural products 0.000 description 22
- 229960000310 isoleucine Drugs 0.000 description 22
- 235000010374 vitamin B1 Nutrition 0.000 description 22
- 239000011691 vitamin B1 Substances 0.000 description 22
- 150000003722 vitamin derivatives Chemical class 0.000 description 21
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 20
- 239000000377 silicon dioxide Substances 0.000 description 19
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 18
- 229930003779 Vitamin B12 Natural products 0.000 description 18
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 18
- 229960004799 tryptophan Drugs 0.000 description 18
- 235000019163 vitamin B12 Nutrition 0.000 description 18
- 239000011715 vitamin B12 Substances 0.000 description 18
- LBPNOPBEVPRCKC-UHFFFAOYSA-N 2-amino-5-hydroxybenzoic acid;hydrochloride Chemical class Cl.NC1=CC=C(O)C=C1C(O)=O LBPNOPBEVPRCKC-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 229930182844 L-isoleucine Natural products 0.000 description 14
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
- 239000004472 Lysine Substances 0.000 description 11
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 229960003136 leucine Drugs 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229960003646 lysine Drugs 0.000 description 11
- 235000018977 lysine Nutrition 0.000 description 11
- 239000013558 reference substance Substances 0.000 description 11
- 235000019157 thiamine Nutrition 0.000 description 11
- 239000011721 thiamine Substances 0.000 description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000012856 packing Methods 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000006187 pill Substances 0.000 description 10
- 235000008521 threonine Nutrition 0.000 description 10
- -1 compound amino acid Chemical class 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 230000035764 nutrition Effects 0.000 description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 9
- 235000008729 phenylalanine Nutrition 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000010812 external standard method Methods 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000007931 coated granule Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940126678 chinese medicines Drugs 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940054665 calcium pantothenate 5 mg Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940036630 folic acid 0.2 mg Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 230000022558 protein metabolic process Effects 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 235000016236 parenteral nutrition Nutrition 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910003978 SiClx Inorganic materials 0.000 description 2
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000012850 discrimination method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000003760 hair shine Effects 0.000 description 2
- 239000008236 heating water Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- JKCNXKXYMRTCQZ-UHFFFAOYSA-N pentane-1-sulfonic acid;sodium Chemical compound [Na].CCCCCS(O)(=O)=O JKCNXKXYMRTCQZ-UHFFFAOYSA-N 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000019191 thiamine mononitrate Nutrition 0.000 description 2
- 239000011748 thiamine mononitrate Substances 0.000 description 2
- 229960004860 thiamine mononitrate Drugs 0.000 description 2
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 2
- KBCPMQUSOLSAQO-UHFFFAOYSA-N (4-carboxyphenyl)azanium;chloride Chemical group Cl.NC1=CC=C(C(O)=O)C=C1 KBCPMQUSOLSAQO-UHFFFAOYSA-N 0.000 description 1
- HYNQTSZBTIOFKH-UHFFFAOYSA-N 2-Amino-5-hydroxybenzoic acid Chemical class NC1=CC=C(O)C=C1C(O)=O HYNQTSZBTIOFKH-UHFFFAOYSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UHXWLHYMUGRLKG-UHFFFAOYSA-N [Mg].O[Si](O)(O)O Chemical compound [Mg].O[Si](O)(O)O UHXWLHYMUGRLKG-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- DPRNENKPXAZQBI-UHFFFAOYSA-N alpha-Vitamin A Natural products OCC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C DPRNENKPXAZQBI-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- VWSRWGFGAAKTQG-UHFFFAOYSA-N ammonium benzoate Chemical compound [NH4+].[O-]C(=O)C1=CC=CC=C1 VWSRWGFGAAKTQG-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 229940076134 benzene Drugs 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940095463 folic acid 0.5 mg Drugs 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940089784 niacinamide 20 mg Drugs 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055705 pangamic acid Drugs 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 108700024047 pangamic acid Proteins 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- ROBLTDOHDSGGDT-UHFFFAOYSA-M sodium;pentane-1-sulfonate Chemical compound [Na+].CCCCCS([O-])(=O)=O ROBLTDOHDSGGDT-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940033282 vitamin b6 2 mg Drugs 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of capsule, which includes capsule shells and is wrapped in the capsule shells and is in powder or granular filler;The capsule shells are using gelatin as gelatin hollow capsule made of key component, and the filler includes active material and pharmaceutic adjuvant.Present invention proportioning science, reasonable, the stability of product is good, has no toxic side effect, safe, has good biological effect, can apply and prepare treatment Chronic Liver, kidney diaseases drug, in alleviation and elimination training physical fatigue food.Capsule of the present invention has the characteristics that be better than the prior art.
Description
Technical field
The present invention relates to a kind of capsule medicaments and preparation method thereof, are to be related to a kind of including 8 kinds of amino acid and 11 specifically
The capsule of kind vitamin micro pill, also referred to as compound amino acid capsule, further relate to the preparation method of the capsule.
Background technology
Protein is the material base of human life activity, human body items physiological function, especially immune function, cell damage
The repair function and growth and development function of wound, with its be metabolized it is normal whether have extremely close relationship.Under normal circumstances, people
Body is to obtain various amino acid by the protein in food to ensure the normal of body protein metabolism.It is closed in human body protein
At in required 20 kinds of amino acid, wherein it is essential amino acid to have 8 kinds of amino acid, this 8 kinds of amino acid are that body is interior originally
Body cannot synthesize and be necessarily dependent upon external supply.They are isoleucine, leucine, lysine, phenylalanine, Soviet Union's ammonia
Acid, valine, methionine and tryptophan.Protein is synthesized, this 8 kinds of amino acid are indispensable, and in content deficiency
Or the synthesis of protein can be all influenced when matching unbalanced.
The generation of disease, development and recovery from illness during, due to various pathology and stress reaction, it is in addition improper diet or
Digestive tract function is affected, and usually will appear the disorder of protein metabolism, and the disorder of protein metabolism is often led with disease
The duration of the death of cause, the generation of complication and disease is closely related.Therefore, in clinical practice, the supply of nitrogen matter is
Indispensable, effective treatment means.
Since World War II, the U.S. takes the lead in releasing protein hydrolysate, the supply for nitrogen matter in lysis.50
In the age, Japan realizes the large scale fermentation of amino acid and prepared by purifying, and advantageous skill is provided for crystal type amino acid transfusion
Art ensures.Into the 1970s and 1980s, amino acid transfusion constantly for clinically all kinds of acute diseases, seriously disease treatment, especially pair
Urgent patient and the treatment for being unable to oral consumption patient provide strong support.
But for the treatment of chronic disease, especially can oral consumption patient treatment, the limitation right and wrong of amino acid transfusion
It is often apparent.In terms of the characteristics of being metabolized from vivo acid, amino acid transfusion may cause vivo acid proportioning it is not normal, be infused
Serum amino acid concentration declines rapidly, aggravates liver denitrogen and bear, simultaneously after serum amino acid excessive concentration in journey, infusion stop
It is possible that causing the adverse reactions such as infusion reaction, vein blood vessel inflammation.What is more important amino acid transfusion is only in short
In play the role of promote positive nitrogen equilibrium, be used for a long time therapeutic effect unobvious.
Just because of this, while parenteral nutrition develops, development abroad is simultaneously perfect by crystalline amino acid, hydrolysis egg
In vain, a variety of enteral nutrition preparations of the nitrogen sources such as complete protein composition.Enteral nutrition preparation is mainly orally ingested, and providing must
The nutrient needed meets the needs of body metabolism, and enteral nutrition is conducive to keep enteron aisle structure and function compared with parenteral nutrition
Integrality prevents intestinal mucosa atrophy and bacterial translocation caused by long-term parenteral, is conducive to the immunity for improving body.
Currently, the treatment of enteral nutrition is paid much attention in clinical practice both at home and abroad, especially in the long-term treatment of chronic disease
In, the ratio of enteral nutrition treatment greatly exceeds the treatment of parenteral nutrition.As long as " gastrointestinal function allows, and uses enteral as possible
Nutrition " is the principle of clinic nutrition treatment.Therefore, people are badly in need of solving the drug for enteral nutrition treatment.Due to amino acid
It is unstable, it causes Amino Acid Oral Preparation product stability poor, restricts the application of Amino Acid Oral Preparation product.For this purpose, this
Field technology personnel attempt the new preparation comprising amino acid and vitamin of exploitation and have successfully pushed them to clinic.
Chinese Patent Application No. 021586195 (ten thousand Hes, CN1424027A) is related to a kind of composite amino acid capsule and its system
Preparation Method.The invention product includes that a variety of supplementary materials such as 8 kinds of amino acid, 11 kinds of vitamin form, specific formula and preparation method,
The invention product advantage is:Proportioning is reasonable, science, has good biological effect, technique uniqueness, advanced, convenient oral, nothing
Toxic side effect, it is safe, it obtains doctor and patient welcomes.Product of the present invention is used for Chronic Liver, kidney and other disease treatments.
Chinese Patent Application No. 200410100003.9 (holy and, CN1781486A) discloses a kind of amino acid and dimension
Raw cellulose capsule preparation, it includes amino acid coated granules and vitamin coated granule, wherein amino acid coated granule and vitamin
The weight ratio of coated granule is 1: 0.68, wherein the amino acid coated granule includes isoleucine, leucine, the bad ammonia of hydrochloric acid
Acid, phenylalanine, methionine, threonine, tryptophan, valine and R-gene, the vitamin coated granule include dimension
Raw element B1 nitrate, vitamin B2, vitamin B6, Vitwas E and niacinamide.The invention, which additionally provides, prepares compound ammonia
The method of base acid and vitamine capsule preparation.
Chinese Patent Application No. 200910153422.1 (Sai Li, CN102038691A) discloses a kind of vitamin amino acid
Compound formulation is coated by multi-vitamins and compound amino acid and is prepared into pellet and obtains.It is believed that the dimension life obtained by the invention
Plain amino acid composite preparation, is compounded with multivitamin and amino acid is easy to use, is improved using pellet sustained release coating technology
Bioavilability, stable quality, absorption of human body are fast.
Chinese Patent Application No. 201010102505.0 (ten thousand Hes, CN101773512A) disclose a kind of 8 kinds of amino acid and
11 kinds of vitamin micro pill capsules and preparation method thereof, including 7 kinds of microspheric granulas, 7 kinds of microspheric granulas are by following parts by weight
Raw material forms:2.66~9.9 parts of thiamine mononitrate pellet, 16.35~20.5 parts of vitamin micro pill a, amino acid pellet a 35.0~
44.1 parts, vitamin micro pill b11.4~14.4 part, amino acid pellet b 6.65~10.5, vitamin C micro-pill 12.73~16.0
Part, 5.7~9.36 parts of vitaminAD microballon.Invention proportioning science, reasonable, the stability of product is good, has no toxic side effect, safety
Property it is high, there is good biological effect, can apply and prepare treatment Chronic Liver, kidney diaseases drug, alleviate and eliminate movement
In training physical fatigue food.
Chinese Patent Application No. 201310055941.0 (ten thousand Hes, CN103142633A) discloses a kind of amino acid glue
Capsule (8-11) and preparation method thereof.In particular to it is a kind of include 8 kinds of amino acid and 11 kinds of vitamin micro pills capsule, also
It is related to the preparation method of the capsule.The capsule include 7 kinds of microspheric granulas, 7 kinds of microspheric granulas by following parts by weight raw material
Composition:2.66~9.9 parts of thiamine mononitrate pellet, 16.35~20.5 parts of vitamin micro pill a, amino acid pellet a 35.0~44.1
Part, 11.4~14.4 parts of vitamin micro pill b, amino acid pellet b 6.65~10.5,12.73~16.0 parts of vitamin C micro-pill,
5.7~9.36 parts of vitaminAD microballon.It is believed that the invention matches, science, reasonable, the stability of product is good, has no toxic side effect, and pacifies
Quan Xinggao has good biological effect, can apply and prepare treatment Chronic Liver, kidney diaseases drug, alleviate and eliminate fortune
In dynamic training physical fatigue food.It is believed that the invention capsule has the characteristics that be better than the prior art.
Regrettably, the above-mentioned prior art is when preparing the preparation comprising 8 kinds of amino acid and 11 kinds of vitamin
Piller is made in amino acid and/or vitamin, is then coated, then coated pellets are divided in empty hard softgel shell.
This preparation process has notable higher production cost than it in the encapsulated technique of conventional powder/granule, this to be produced into
This will be that patient person's medication brings huge medical burden.
Therefore, develop it is a kind of meet the drug standards require and simple production process comprising 8 kinds of amino acid and 11 kinds dimension
The compound amino acid capsule of raw element is that those skilled in the art extremely expect.
Invention content
The present invention goal of the invention be to provide a kind of capsule containing 8 kinds of amino acid and 11 kinds of vitamins, expect this
Kind capsule has the characteristics that simple production process and has excellent pharmacy quality.The present invention it has been unexpectedly discovered that
It is fully able to realize above-mentioned mesh using the capsule containing 8 kinds of amino acid and 11 kinds of vitamins that the method for the present invention is prepared
's.It finds and is accomplished the present invention is based on this.
In the present invention, the capsule refers to hard capsule well known to art of pharmacy, usual to be different from people
The soft capsule known.Hard capsule includes typically capsule shells (also commonly referred to as Capsules) and is wrapped in the capsule
Filler in shell, the filler is usually in powder or graininess, wherein adding comprising active constituents of medicine and when necessary
Pharmaceutic adjuvant.Known in pharmaceutical field technical staff, for capsule especially hard capsule, inside capsule shells are filled upper
Filler is stated, also known as " content ".In upper and lower each embodiment of text of the invention, the various fillers being prepared are filled into
Suitable in the Capsules of size, making the content be filled substantially with capsule body, then capsule cap fitting is sealed.
In the first aspect of the present invention, a kind of capsule is provided comprising capsule shells and be wrapped in the capsule shells
And it is in powder or granular filler;The capsule shells be using gelatin as gelatin hollow capsule made of key component, it is described
Filler includes active material and pharmaceutic adjuvant;The active material includes:
Capsule according to the present invention, each grain include that the amount of active material is:
L-Leu | 14.5~22mg | L-Isoleucine | 4.5~7mg |
L-Lysine hydrochloride | 20~30mg | L-phenylalanine | 4~6mg |
L-threonine | 3.3~5mg | Valine | 5.3~8mg |
L-Trp | 4~6mg | Methionine (for example, L-Methionine or DL- METHIONINE) | 14.5~22mg |
Vitamin A | 1600~2400IU | Calciferol | 160~240IU |
Vitamin B1 (or sulfuric acid thiamine) | 4~6mg | Vitamin B2 | 2.4~3.6mg |
Niacinamide | 1.6~25mg | Vitamin B6 | 2~3mg |
Folic acid | 0.16~0.24mg | Calcium pantothenate | 4~6mg |
Vitamin B12 | 0.8~1.2ug | Vitamin C | 16~24mg |
Vitamin E | 0.8~1.2mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.16~0.24mg |
Capsule according to the present invention, each grain include that the amount of active material is:
L-Leu | 16.5~20mg | L-Isoleucine | 5.3~6.5mg |
L-Lysine hydrochloride | 22.5~27.5mg | L-phenylalanine | 4.5~5.5mg |
L-threonine | 3.7~4.6mg | Valine | 6~7.5mg |
L-Trp | 4.5~5.5mg | Methionine (for example, L-Methionine or DL- METHIONINE) | 16.5~20mg |
Vitamin A | 1800~2200IU | Calciferol | 180~220IU |
Vitamin B1 (or sulfuric acid thiamine) | 4.5~5.5mg | Vitamin B2 | 2.7~3.3mg |
Niacinamide | 1.8~22mg | Vitamin B6 | 2.25~2.75mg |
Folic acid | 0.18~0.22mg | Calcium pantothenate | 4.5~5.5mg |
Vitamin B12 | 0.9~1.1ug | Vitamin C | 18~22mg |
Vitamin E | 0.9~1.1mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.18~0.22mg |
Capsule according to the present invention, each grain include that the amount of active material is about:
L-Leu | 18.3mg | L-Isoleucine | 5.9mg |
L-Lysine hydrochloride | 25mg | L-phenylalanine | 5mg |
L-threonine | 4.2mg | Valine | 6.7mg |
L-Trp | 5mg | Methionine (for example, L-Methionine or DL- METHIONINE) | 18.4mg |
Vitamin A | 2000IU | Calciferol | 200IU |
Vitamin B1 (or sulfuric acid thiamine) | 5mg | Vitamin B2 | 3mg |
Niacinamide | 2mg (or 20mg) | Vitamin B6 | 2.5mg |
Folic acid | 0.2mg | Calcium pantothenate | 5mg |
Vitamin B12 | 1ug | Vitamin C | 20mg |
Vitamin E | 1mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.2mg |
Capsule according to the present invention, wherein the pharmaceutic adjuvant is selected from following one or more:Lactose, shallow lake
Powder, microcrystalline cellulose, dextrin, sucrose, silicea, hydroxypropyl methyl cellulose, carboxymethyl starch, sodium carboxymethyl starch, methyl are fine
Tie up element, ethyl cellulose etc..
Capsule according to the present invention, the pharmaceutic adjuvant total amount for including in each grain are 80~400mg.
Capsule according to the present invention, the pharmaceutic adjuvant total amount for including in each grain are 100~350mg.
Capsule according to the present invention, the pharmaceutic adjuvant total amount for including in each grain are 100~300mg.
Capsule according to the present invention, wherein the pharmaceutic adjuvant includes:Starch and silicea.
Capsule according to the present invention, wherein the silicea is the pharmaceutic adjuvant containing element silicon.Such as it is selected from dioxy
SiClx, colloidal silicon dioxide, talcum powder etc..As Chinese Pharmacopoeia version four in 2015 is recorded, silica and colloidal silica
Silicon is two different substances.Colloidal silicon dioxide is also known as superfine silica gel powder.
Capsule according to the present invention, the amount of starch for including in each grain are 80~350mg.
Capsule according to the present invention, the amount of starch for including in each grain are 100~300mg.
Capsule according to the present invention, the amount of starch for including in each grain are 100~250mg.
Capsule according to the present invention, the silicea for including in each grain account for the 0.2~10% of the filler weight.
Capsule according to the present invention, the silicea for including in each grain account for the 0.5~5% of the filler weight.
Capsule according to the present invention, the silicea for including in each grain account for the 0.5~3% of the filler weight.
The weight of capsule according to the present invention, the filler for including in each grain is 200~500mg.
The weight of capsule according to the present invention, the filler for including in each grain is 225~450mg.
The weight of capsule according to the present invention, the filler for including in each grain is 250~400mg.
The granularity of capsule according to the present invention, filler is:99% or more particle can be sieved by 20 mesh.
The granularity of capsule according to the present invention, filler is:99% or more particle can be sieved by 24 mesh.
The granularity of capsule according to the present invention, filler is:95% or more particle can be sieved by 50 mesh.
The granularity of capsule according to the present invention, filler is:90% or more particle can be sieved by 65 mesh.
Capsule according to the present invention, is prepared by method comprising the following steps:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Each material of the present invention can be uniformly mixed by well-mixed technique.Certainly, in order to improve mixing efficiency, also
It can be by the small several components of dosage, such as vitamin A, calciferol, folic acid, vitamin B12, vitamin E, 5- hydroxyl neighbour's phenalgins
Carboxylic acid hydrochloride etc. is suspended with ethyl alcohol, then is sprayed in all or part of rest activity substance and/or pharmaceutic adjuvant, to be removed
After solvent, it is uniformly mixed with the active material of surplus and/or pharmaceutic adjuvant.The present inventor is by verifying discovery, different mixing
Method in addition to mixture homogeneity in timeliness it is variant other than, when in every capsule various contents less than/be equal to 5mg activity
When substance reaches calculating formula A+1.45S≤15.0 (two annex XE institutes support methods of Chinese Pharmacopoeia version in 2010) of uniformity of dosage units
(hereafter whole capsules made from each embodiment, wherein the active material that various contents are less than/are equal to 5mg is computed their A
+ 1.45S is in 6.2~12.5 ranges), capsule made from these different mixing modes is detected in stability test of the present invention
In do not show difference, i.e., different mixing modes to the stability of product and have no significant effect.
Further, second aspect of the present invention provides the method for preparing capsule, the capsule include capsule shells with
And it is wrapped in the capsule shells and is in powder or granular filler;The capsule shells are using gelatin as made of key component
Gelatin hollow capsule, the filler include active material and pharmaceutic adjuvant;The active material includes:
L-Leu | L-Isoleucine |
L-Lysine hydrochloride | L-phenylalanine |
L-threonine | Valine |
L-Trp | Methionine (for example, L-Methionine or DL- METHIONINE) |
Vitamin A | Calciferol |
Vitamin B1 (or sulfuric acid thiamine) | Vitamin B2 |
Niacinamide | Vitamin B6 |
Folic acid | Calcium pantothenate |
Vitamin B12 | Vitamin C |
Vitamin E | 5- hydroxyl anthranilic acid hydrochlorides; |
This approach includes the following steps:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
According to the method for the present invention, each grain of the capsule includes that the amount of active material is:
L-Leu | 14.5~22mg | L-Isoleucine | 4.5~7mg |
L-Lysine hydrochloride | 20~30mg | L-phenylalanine | 4~6mg |
L-threonine | 3.3~5mg | Valine | 5.3~8mg |
L-Trp | 4~6mg | Methionine (for example, L-Methionine or DL- METHIONINE) | 14.5~22mg |
Vitamin A | 1600~2400IU | Calciferol | 160~240IU |
Vitamin B1 (or sulfuric acid thiamine) | 4~6mg | Vitamin B2 | 2.4~3.6mg |
Niacinamide | 1.6~25mg | Vitamin B6 | 2~3mg |
Folic acid | 0.16~0.24mg | Calcium pantothenate | 4~6mg |
Vitamin B12 | 0.8~1.2ug | Vitamin C | 16~24mg |
Vitamin E | 0.8~1.2mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.16~0.24mg |
According to the method for the present invention, each grain of the capsule includes that the amount of active material is:
L-Leu | 16.5~20mg | L-Isoleucine | 5.3~6.5mg |
L-Lysine hydrochloride | 22.5~27.5mg | L-phenylalanine | 4.5~5.5mg |
L-threonine | 3.7~4.6mg | Valine | 6~7.5mg |
L-Trp | 4.5~5.5mg | Methionine (for example, L-Methionine or DL- METHIONINE) | 16.5~20mg |
Vitamin A | 1800~2200IU | Calciferol | 180~220IU |
Vitamin B1 (or sulfuric acid thiamine) | 4.5~5.5mg | Vitamin B2 | 2.7~3.3mg |
Niacinamide | 1.8~22mg | Vitamin B6 | 2.25~2.75mg |
Folic acid | 0.18~0.22mg | Calcium pantothenate | 4.5~5.5mg |
Vitamin B12 | 0.9~1.1ug | Vitamin C | 18~22mg |
Vitamin E | 0.9~1.1mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.18~0.22mg |
According to the method for the present invention, each grain of the capsule includes that the amount of active material is about:
L-Leu | 18.3mg | L-Isoleucine | 5.9mg |
L-Lysine hydrochloride | 25mg | L-phenylalanine | 5mg |
L-threonine | 4.2mg | Valine | 6.7mg |
L-Trp | 5mg | Methionine (for example, L-Methionine or DL- METHIONINE) | 18.4mg |
Vitamin A | 2000IU | Calciferol | 200IU |
Vitamin B1 (or sulfuric acid thiamine) | 5mg | Vitamin B2 | 3mg |
Niacinamide | 2mg (or 20mg) | Vitamin B6 | 2.5mg |
Folic acid | 0.2mg | Calcium pantothenate | 5mg |
Vitamin B12 | 1ug | Vitamin C | 20mg |
Vitamin E | 1mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.2mg |
According to the method for the present invention, wherein the pharmaceutic adjuvant is selected from following one or more:Lactose, starch,
Microcrystalline cellulose, dextrin, sucrose, silicea, hydroxypropyl methyl cellulose, carboxymethyl starch, sodium carboxymethyl starch, Methyl cellulose
Element, ethyl cellulose etc..
According to the method for the present invention, the pharmaceutic adjuvant total amount for including in each grain of the capsule is 80~400mg.
According to the method for the present invention, the pharmaceutic adjuvant total amount for including in each grain of the capsule is 100~350mg.
According to the method for the present invention, the pharmaceutic adjuvant total amount for including in each grain of the capsule is 100~300mg.
According to the method for the present invention, the pharmaceutic adjuvant described in the capsule includes:Starch and silicea.
According to the method for the present invention, the amount of starch for including in each grain of the capsule is 80~350mg.
According to the method for the present invention, the amount of starch for including in each grain of the capsule is 100~300mg.
According to the method for the present invention, the amount of starch for including in each grain of the capsule is 100~250mg.
According to the method for the present invention, the silicea for including in each grain of the capsule account for the filler weight 0.2~
10%.
According to the method for the present invention, the silicea for including in each grain of the capsule account for the filler weight 0.5~
5%.
According to the method for the present invention, the silicea for including in each grain of the capsule account for the filler weight 0.5~
3%.
According to the method for the present invention, the weight for the filler for including in each grain of the capsule is 200~500mg.
According to the method for the present invention, the weight for the filler for including in each grain of the capsule is 225~450mg.
According to the method for the present invention, the weight for the filler for including in each grain of the capsule is 250~400mg.
According to the method for the present invention, the granularity of the capsule filler is:99% or more particle can be sieved by 20 mesh.
According to the method for the present invention, the granularity of the capsule filler is:99% or more particle can be sieved by 24 mesh.
According to the method for the present invention, the granularity of the capsule filler is:95% or more particle can be sieved by 50 mesh.
According to the method for the present invention, the granularity of the capsule filler is:90% or more particle can be sieved by 65 mesh.
According to the method for the present invention, wherein vitamin A, calciferol, folic acid, vitamin B12, vitamin E, 5- hydroxyls are adjacent
Aminobenzoic Acid hydrochloride etc. is suspended with ethyl alcohol and is sprayed to all or part of rest activity substance and/or pharmaceutic adjuvant again
In, it after solvent to be removed, is uniformly mixed with the active material of surplus and/or pharmaceutic adjuvant, mixed powder eventually is made.
Gelatin hollow capsule of the present invention has typically been recorded to version in 2010《Chinese Pharmacopoeia》Two, and have perhaps
Multi-product is ratified to list by state food pharmaceuticals administration general bureau, such as Chinese medicines quasi-word F20020009 (Shaoxing Renhe),
The gelatin hollow capsule of Chinese medicines quasi-word F20020035 (life of Zhejiang enlightening) and Chinese medicines quasi-word F20030004 (the long standing grain in Jiangsu).
Capsule according to the present invention is that the directly encapsulated mode of powder is prepared.
8 kinds of amino acid of one kind of the invention and 11 kinds of vitamin micro pill capsules are preparing treatment Chronic Liver, kidney diaseases drug, delay
Application in solution and elimination training physical fatigue food.
In the case of chronic hepatic diseases, it can be effectively improved on the basis of not increasing patient's nitrogen matter and draining burden
Cell promotes the 8 kinds of amino acid and 11 kinds of vitamine capsule techniques of the biosynthesis of protein to the bioavailability of amino acid
Unique, the technologically advanced, term of validity is more than 3 years, and product of the present invention is used for Chronic Liver, kidney and other disease treatments, alleviates and eliminates
Physical fatigue.
The present invention has protrusion excellent as the enteral nutrition preparation for improving nitrogen source amino acid composition in chronic disease therapy
Gesture.First, it haves no need to change the dietary structure and other treatment schemes of patient, it will be able to significantly improve the amino acid of patient
With protein metabolism;Secondly, in the case of chronic hepatic diseases, it can be on the basis for not increasing patient's nitrogen matter excretion burden
On effectively improve bioavailability of the cell to amino acid, promote the biosynthesis of protein.The present invention and existing amino acid
Product technology compares, and has the following advantages that:
1. proportioning is reasonable, science, there is good biological effect.Its different and general amino acid preparation, 8 kinds must
It needs the ratio of amino acid to combine Asian-Pacific area dietary protein structure, amino acid composition and absorption of human body many factors synthesis to examine
Consider and determine, wherein the large percentage of branched-chain amino acid, lysine, methionine, while adding 11 kinds of vitamins, gives full play to amino
The synergistic effect of acid and vitamin makes amino acid is balanced in human body to absorb, ensures the bioavailability of amino acid.
2. technique is unique, advanced, solve the disadvantage that other Moriamin Forte preparations, by 8 kinds of essential amino acids and 11 kinds
Between can guarantee each ingredient chemical reaction and degradation will not occur in storage period for vitamin mixing, improve various work in product
The stability of property ingredient.
3. convenient oral.Moriamin Forte preparation is in the treatment that patients with chronic diseases needs amino acid preparation for a long time, energy
Enough make up certain deficiencies of amino acid transfusion.The present invention is particularly suited for the chronic of Long-term taking medicine, both alleviates patient
Financial burden, while the psychological bearing capability of patient is improved again.
The capsule that various embodiments of the present invention are prepared, keeps sample for a long time at ambient temperature, respectively at 0,3,6,9,
12, it samples within 18,24,36 months, by hereafter contained method, in conjunction with the assay method of two records of version Chinese Pharmacopoeia in 2010, to not
Sample with the time is measured indices.The results show that 0 month sample to keep sample to 36 months of various embodiments of the present invention, 8 kinds of ammonia
The content of base acid was respectively maintained within 3 years periods in 94~105% ranges of labelled amount, the content of 11 kinds of vitamin
It was respectively maintained in 95~103% ranges of labelled amount within 3 years periods, shows that capsule of the present invention fully meets medicine
The requirement of quality standard.
Specific implementation mode
The following examples are used for further illustrating the present invention, but this does not imply that any limitation of the invention.
In following experiment, when preparing capsule of the present invention, prepared per the batch of at least 20,000 in terms of capsule number amounts of batch, but
It is to be indicated with every amount when listing formula.In following experiment, when preparing capsule of the present invention, in addition do not say such as
Bright, the granularity of capsule filler is:95% or more particle can be sieved by 50 mesh.In following experiment, the present invention is prepared
When capsule, if not otherwise indicated, Capsules used are gelatin hollow capsules.
Embodiment 1:Prepare capsule
Formula:
L-Leu | 18.3mg | L-Isoleucine | 5.9mg |
L-Lysine hydrochloride | 25mg | L-phenylalanine | 5mg |
L-threonine | 4.2mg | Valine | 6.7mg |
L-Trp | 5mg | DL- METHIONINE | 18.4mg |
Vitamin A | 2000IU | Calciferol | 200IU |
Vitamin B1 | 5mg | Vitamin B2 | 3mg |
Niacinamide | 2mg | Vitamin B6 | 2.5mg |
Folic acid | 0.2mg | Calcium pantothenate | 5mg |
Vitamin B12 | 1ug | Vitamin C | 20mg |
Vitamin E | 1mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.2mg |
Starch | 170mg | Silica * | 2% |
Note:* silicea (silica) is fed intake with the percentage of capsule filling total weight, similarly hereinafter.
Preparation method 1:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Preparation method 2:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) by vitamin A, calciferol, folic acid, vitamin B12, vitamin E, 5- hydroxyl anthranilic acid hydrochlorides
Six are sprayed to ethyl alcohol (dosage is 3 times of this 6 kinds of active material total weights) suspension in the starch of 1/3 amount again, to be dried to remove
It after removing solvent, is uniformly mixed with the active material of surplus and/or pharmaceutic adjuvant, mixed powder eventually is made;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Two batches capsule is made by both the above method.It is when hereafter involved in each test example to 1 sample of embodiment
Refer to 1 gained capsule of preparation method or is prepared according to preparation method 1;But in each test example 2 two kinds of capsules of preparation method 1 and preparation method without
Notable difference.
The gelatin hollow capsule that the present embodiment uses is F20020009, when being hereafter not indicated otherwise, also uses the hollow glue
Capsule.
Embodiment 2:Prepare capsule
Formula:
L-Leu | 18.3mg | L-Isoleucine | 5.9mg |
L-Lysine hydrochloride | 25mg | L-phenylalanine | 5mg |
L-threonine | 4.2mg | Valine | 6.7mg |
L-Trp | 5mg | L-Methionine | 18.4mg |
Vitamin A | 2000IU | Calciferol | 200IU |
Sulfuric acid thiamine | 5mg | Vitamin B2 | 3mg |
Niacinamide | 20mg | Vitamin B6 | 2.5mg |
Folic acid | 0.2mg | Calcium pantothenate | 5mg |
Vitamin B12 | 1ug | Vitamin C | 20mg |
Vitamin E | 1mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.2mg |
Starch | 180mg | Silica | 2% |
Preparation method:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually, (its granularity is:90% or more particle can be sieved by 65 mesh);
(iii) mixed powder eventually is filled into hard capsule case (F20020035), capsule body and capsule cap is set with, sealing,
To obtain the final product.
Embodiment 3:Prepare capsule
Formula:
L-Leu | 14.5mg | L-Isoleucine | 4.5mg |
L-Lysine hydrochloride | 30mg | L-phenylalanine | 6mg |
L-threonine | 3.3mg | Valine | 5.3mg |
L-Trp | 6mg | DL- METHIONINE | 22mg |
Vitamin A | 1600IU | Calciferol | 160IU |
Vitamin B1 | 6mg | Vitamin B2 | 2.4mg |
Niacinamide | 1.6mg | Vitamin B6 | 3mg |
Folic acid | 0.24mg | Calcium pantothenate | 4mg |
Vitamin B12 | 0.8ug | Vitamin C | 24mg |
Vitamin E | 1.2mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.16mg |
Starch | 100mg | Silica | 5% |
Preparation method:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually, (its granularity is:95% or more particle can be sieved by 65 mesh);
(iii) mixed powder eventually is filled into hard capsule case (F20030004), capsule body and capsule cap is set with, sealing,
To obtain the final product.
Embodiment 4:Prepare capsule
Formula:
Preparation method:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Embodiment 5:Prepare capsule
Formula:
L-Leu | 16.5mg | L-Isoleucine | 5.3mg |
L-Lysine hydrochloride | 27.5mg | L-phenylalanine | 5.5mg |
L-threonine | 3.7mg | Valine | 6mg |
L-Trp | 5.5mg | DL- METHIONINE | 20mg |
Vitamin A | 1800IU | Calciferol | 180IU |
Vitamin B1 | 5.5mg | Vitamin B2 | 3.3mg |
Niacinamide | 1.8mg | Vitamin B6 | 2.25mg |
Folic acid | 0.22mg | Calcium pantothenate | 5.5mg |
Vitamin B12 | 0.9ug | Vitamin C | 18mg |
Vitamin E | 1.1mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.22mg |
Starch | 250mg | Silica | 5% |
Preparation method:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Embodiment 6:Prepare capsule
Formula:
L-Leu | 20mg | L-Isoleucine | 6.5mg |
L-Lysine hydrochloride | 22.5mg | L-phenylalanine | 4.5mg |
L-threonine | 4.6mg | Valine | 7.5mg |
L-Trp | 4.5mg | DL- METHIONINE | 16.5mg |
Vitamin A | 2200IU | Calciferol | 220IU |
Vitamin B1 | 4.5mg | Vitamin B2 | 2.7mg |
Niacinamide | 2.2mg | Vitamin B6 | 2.75mg |
Folic acid | 0.18mg | Calcium pantothenate | 4.5mg |
Vitamin B12 | 1.1ug | Vitamin C | 22mg |
Vitamin E | 0.9mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.18mg |
Starch | 150mg | Silica | 10% |
Preparation method:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Embodiment 7:Prepare capsule
Formula:
L-Leu | 14.5mg | L-Isoleucine | 7mg |
L-Lysine hydrochloride | 30mg | L-phenylalanine | 4mg |
L-threonine | 3.3mg | Valine | 8mg |
L-Trp | 6mg | L-Methionine | 14.5mg |
Vitamin A | 1600IU | Calciferol | 240IU |
Sulfuric acid thiamine | 6mg | Vitamin B2 | 2.4mg |
Niacinamide | 16mg | Vitamin B6 | 3mg |
Folic acid | 0.24mg | Calcium pantothenate | 4mg |
Vitamin B12 | 0.8ug | Vitamin C | 24mg |
Vitamin E | 1.2mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.16mg |
Starch | 150mg | Silica | 0.5% |
Preparation method:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Embodiment 8:Prepare capsule
Formula:
L-Leu | 22mg | L-Isoleucine | 4.5mg |
L-Lysine hydrochloride | 20mg | L-phenylalanine | 6mg |
L-threonine | 5mg | Valine | 5.3mg |
L-Trp | 4mg | L-Methionine | 22mg |
Vitamin A | 2400IU | Calciferol | 160IU |
Sulfuric acid thiamine | 4mg | Vitamin B2 | 3.6mg |
Niacinamide | 25mg | Vitamin B6 | 2mg |
Folic acid | 0.16mg | Calcium pantothenate | 6mg |
Vitamin B12 | 1.2ug | Vitamin C | 16mg |
Vitamin E | 0.8mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.24mg |
Starch | 180mg | Silica | 3% |
Preparation method:It is prepared according to 1 preparation method 2 of embodiment.
Embodiment 9:Prepare capsule
Formula:
Preparation method:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Embodiment 10:Prepare capsule
Formula:
L-Leu | 16.5mg | L-Isoleucine | 6.5mg |
L-Lysine hydrochloride | 27.5mg | L-phenylalanine | 4.5mg |
L-threonine | 3.7mg | Valine | 7.5mg |
L-Trp | 5.5mg | L-Methionine | 16.5mg |
Vitamin A | 1800IU | Calciferol | 220IU |
Sulfuric acid thiamine | 5.5mg | Vitamin B2 | 2.7mg |
Niacinamide | 18mg | Vitamin B6 | 2.75mg |
Folic acid | 0.22mg | Calcium pantothenate | 4.5mg |
Vitamin B12 | 0.9ug | Vitamin C | 22mg |
Vitamin E | 1.1mg | 5- hydroxyl anthranilic acid hydrochlorides | 0.18mg |
Starch | 150mg | Silica | 1% |
Preparation method:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Embodiment 11:Prepare capsule
It respectively refers to the formula of embodiment 1-10 and preparation method prepares capsule, different is only to replace with silicea therein
Colloidal silicon dioxide (embodiment 1 is prepared according to preparation method 1).
Embodiment 12:Prepare capsule
It respectively refers to the formula of embodiment 1-10 and preparation method prepares capsule, different is only to replace with silicea therein
Talcum powder (embodiment 1 is prepared according to preparation method 1).
Test example 1:The general aspects of capsule is investigated
Whole capsules (filler is usually also known as content in this field) made from foregoing embodiments 1-12 carry out
It investigates
1、【Differentiate】
(1) capsule 1 is taken, water 10ml is added, makes dissolving, is filtered, filtrate adds ninhydrin solution 2ml, heating water bath, solution
Aobvious purple.After testing, above-mentioned testing result is presented in whole capsule samples.
(2) in the chromatography recorded under assay item, the retention time at various amino acid peaks should be to each corresponding reference substance
Retention time it is consistent.After testing, above-mentioned testing result is presented in whole capsule samples.
(3) in the chromatography recorded under assay item, the retention time at various vitamin peaks should be to each corresponding reference substance
Retention time it is consistent.After testing, above-mentioned testing result is presented in whole capsule samples.
(4) it takes the fine powder of this product appropriate (being approximately equivalent to pangamic acid mg), adds sodium hydroxide test solution 2.5ml, the potassium ferricyanide
Test solution 0.5ml and n-butanol 5ml, strength shaking 2 minutes, placement makes layering, upper layer alcohol liquid show strong blue-fluorescence, and acid adding makes
At acidity, fluorescence disappears, then alkali is added to make into alkalinity, and fluorescence shows again.After testing, above-mentioned inspection is presented in whole capsule samples
Survey result.
(5) it takes the fine powder of this product appropriate (being approximately equivalent to vitamin B2 1mg), adds water 100ml, shake, solution is in transmitted light
Lower observation shows pistac and has yellow-green fluorescence, and mine acid or aqueous slkali, fluorescence is added to disappear.After testing, whole capsule examinations
Above-mentioned testing result is presented in sample.
(6) take Capsule content about 2.0g, add water 15ml, boil, let cool, the translucent gel of off-white color
Object;The gelling material about 1ml is taken, iodine test solution 1 is added to drip, that is, shows blue, black-and-blue or atropurpureus, gradually fades after heating.We
Method be check in preparation whether the classical way containing starch, through with amino acid-vitamin mixed-powder ratio for being not added with starch
Compared with or with compared with being not added with the mixed-powder of amino acid-vitamin this method be still reliable, other each groups in prescription
Dividing does not influence starch coloration judgement.After testing, above-mentioned testing result is presented in whole capsule samples.
(7) qualitative/quantitative of silicea:(thank to Xinhua etc., the survey of talcum powder content in different food products with reference to thanking to Xinhua's document
It is fixed, Henan preventive medicine magazine, 2011,22 (1):20) method in measures the content of talcum powder in Capsule content;With
And reference Zhang Yaoli documents (Zhang Yaoli etc., the assay method of Surinam's timber dioxide-containing silica, forestry science and technology exploitation,
2002,16 (4):15) method in measures the content of silica in Capsule content.It is measured with both the above known method
The capsule sample for being all added to silicea show containing talcum powder or silica, and after measured, silicon wherein included
The amount of agent and the inventory of silicea in involved capsule are coincide.In addition, with reference to the four " dioxies recorded of version Chinese Pharmacopoeia in 2015
Discrimination method in SiClx " and " colloidal silicon dioxide ", can also be easy and accurately to the silicea in Capsule content into
Row Qualitive test.
(8) the qualitative determination of main material gelatin used in Capsules:It, can for the gelatin hollow capsule that the present invention uses
Discrimination method in " gelatinum pro capsulae " that is recorded with reference to version Chinese Pharmacopoeia four in 2015, is readily determined Capsules used
Whether shell is made of with gelatin for main material system.
2、【It checks】
(1) loss on drying:This product 10 is taken, content is poured out, after mixing, takes about 1g, it is 1 hour dry at 105 DEG C,
Less loss weight must not cross 4%.(two annex VIII L of Chinese Pharmacopoeia version in 2010).
After testing, whole capsule sample less loss weight are respectively less than 2.6%.
Other inspection items of capsule can refer to related under two annex of Chinese Pharmacopoeia version in 2010, I E capsule agent item
Items regulation carries out, and all capsule testing result meets the general provision of pharmacopeia.
3、【Assay】
(1) amino acid
Content uniformity inspection is carried out to capsule;This product content under content uniformity item is taken, mixing is finely ground, and precision claims
It takes in right amount, with water dissolution and dilutes a certain concentration, filter, take subsequent filtrate as test solution, with amino acid analysis appropriate
Instrument or high performance liquid chromatograph separation determination;Corresponding amino acid reference substance is separately taken, the reference substance solution of respective concentration is made, together
Method measures;By external standard method with the content of each amino acid of calculated by peak area.
(2) vitamin C, niacinamide, vitamin B1, vitamin B6
It is measured according to high performance liquid chromatography (two annex V D of Chinese Pharmacopoeia version in 2010);
Chromatographic condition and system suitability:It is filler with octadecylsilane chemically bonded silica;It is flowing with acetonitrile
Phase A, 0.04% pentanesulfonic acid sodium solution (glacial acetic acid for containing 0.4%) is Mobile phase B, and the regulation according to the form below carries out gradient and washes
It is de-;Flow velocity 1.0ml/min, Detection wavelength 275nm, 25 DEG C of column temperature;Number of theoretical plate should be not less than by the calculating of vitamin C peak
2000;
Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
- 10~0 | 4 | 96 |
0~8 | 4 | 96 |
9~15 | 10 | 90 |
16~27 | 13 | 87 |
Measuring method:This product content under content uniformity item is taken, finely ground, precision weighs appropriate (amount for being approximately equivalent to 1)
It sets in 100ml measuring bottles, 0.01mol/L hydrochloric acid solutions (metaphosphoric acid for containing 0.1%) about 80ml is added, is ultrasonically treated 30 minutes, puts
It is cold, it is diluted to scale, is shaken up, is filtered;Precision measures 10 μ l of subsequent filtrate and injects liquid chromatograph, records chromatogram;It is another that dimension is taken to give birth to
Plain C, vitamin B1, vitamin B6 and niacinamide reference substance are appropriate, accurately weighed, (contain 0.1% with 0.01mol/L hydrochloric acid solutions
Metaphosphoric acid) dissolve and quantify dilution and be made in every 1ml that the mixing containing 0.2mg, 0.05mg, 0.025mg and 0.02mg is molten respectively
Liquid, product solution (interim brand-new), is measured in the same method as a contrast;By external standard method with calculated by peak area to get.
(3) vitamin B2
It is measured according to high performance liquid chromatography (two annex V D of Chinese Pharmacopoeia version in 2010);
Chromatographic condition and system suitability:It is filler with octadecylsilane chemically bonded silica;With acetonitrile -0.04%
Pentanesulfonic acid sodium solution (contain 0.4% glacial acetic acid) (13: 87) be mobile phase, flow velocity 1.0ml/min, Detection wavelength is
267nm, 25 DEG C of column temperature;Number of theoretical plate is calculated by vitamin B2 peak should be not less than 2000;
Measuring method:It is protected from light operation;This product content under content uniformity item is taken, finely ground, precision weighs (to be approximately equivalent in right amount
1 amount) it sets in 100ml measuring bottles, 0.01mol/L hydrochloric acid solutions (metaphosphoric acid for containing 0.1%) about 80ml is added, is ultrasonically treated
It 10 minutes, sets in water-bath and heats 30 minutes, and constantly shake, let cool, be diluted to scale, filter;Precision measures 10 μ l of subsequent filtrate
Liquid chromatograph is injected, chromatogram is recorded;Separately take vitamin B2 reference substance appropriate, it is accurately weighed, with 0.01mol/L hydrochloric acid solutions
(metaphosphoric acid for containing 0.1%) heating water bath makes dissolving, lets cool, and quantify the solution for diluting and being made in every 1ml containing about 0.03mg, makees
For reference substance solution (interim brand-new), it is measured in the same method.By external standard method with calculated by peak area to get.
(4) calcium pantothenate
It is measured according to high performance liquid chromatography (two annex V D of Chinese Pharmacopoeia version in 2010);
Chromatographic condition and system suitability:It is filler with octadecylsilane chemically bonded silica;It is flowing with acetonitrile
Phase A, 0.1% phosphoric acid solution (v/v) is Mobile phase B, and the regulation according to the form below carries out gradient elution;Flow velocity 1.0ml/min, inspection
Survey wavelength is 210nm, and column temperature is 25 DEG C;Number of theoretical plate is calculated by calcium pantothenate peak should be not less than 5000;
Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
- 10~0 | 3 | 97 |
0~22 | 3 | 97 |
23~36 | 15 | 85 |
Measuring method:This product content under content uniformity item is taken, finely ground, precision weighs (is approximately equivalent to calcium pantothenate in right amount
The amount of 12.5mg) it sets in 50ml measuring bottles, 0.1% phosphoric acid solution (v/v) about 40ml is added, is ultrasonically treated 20 minutes, lets cool, it is dilute
It releases to scale, shakes up, filter;Precision measures 10 μ l of subsequent filtrate and injects liquid chromatograph, records chromatogram;Separately calcium pantothenate is taken to compare
Appropriate product, it is accurately weighed, it is dissolved with 0.1% phosphoric acid solution (v/v), and quantify dilution and be made in every 1ml containing about 0.25mg's
Solution, product solution, is measured in the same method as a contrast;By external standard method with calculated by peak area to get.
(5) folic acid
It is measured according to high performance liquid chromatography (two annex V D of Chinese Pharmacopoeia version in 2010);
Chromatographic condition and system suitability:It is filler with octadecylsilane chemically bonded silica;It is flowing with acetonitrile
Phase A, 0.05mol/L potassium dihydrogen phosphate (with phosphoric acid tune pH to 3.0 ± 0.2) are Mobile phase B, and the regulation according to the form below carries out
Gradient elution;Flow velocity 1.0ml/min, Detection wavelength 280nm, column temperature are 35 DEG C, and number of theoretical plate should not be low by the calculating of folic acid peak
In 5000.
Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
0~17 | 9 | 91 |
18~25 | 15 | 85 |
26~30 | 9 | 91 |
Measuring method:It is protected from light operation;This product content under content uniformity item is taken, finely ground, precision weighs (to be approximately equivalent in right amount
The amount of folic acid 0.5mg) it sets in 25ml measuring bottles, 0.2% sodium carbonate liquor about 20ml is added, shaking makes to be uniformly dispersed, and places 30 points
Clock is ultrasonically treated 30 minutes, lets cool, be diluted to scale, shake up, and filters;Precision measures 10 μ l of subsequent filtrate and injects liquid chromatograph,
Record chromatogram;It is another to take folic acid reference substance about 10mg, it is accurately weighed, it sets in 50ml measuring bottles, 0.2% sodium carbonate liquor 10ml is added
Make dissolving, is diluted with water to scale, as a contrast product concentrated wiring liquid;Precision measures reference substance concentrated wiring liquid 1.0ml, sets 10ml measuring bottles
In, it is diluted with water to scale, the solution containing about 0.02mg in every 1ml is made, as a contrast product solution (interim brand-new), same to method
It measures.By external standard method with calculated by peak area to get.
(6) vitamin A, calciferol, vitamin E
It is measured according to high performance liquid chromatography (two annex VD of Chinese Pharmacopoeia version in 2010);
Chromatographic condition and system suitability:It is filler with octadecylsilane chemically bonded silica;With methanol-water (98:
2) it is mobile phase;Flow velocity is 0.6ml/min, and Detection wavelength 265nm, column temperature is 25 DEG C;Number of theoretical plate respectively press vitamin A,
Calciferol, vitamin E peak, which calculate, should be not less than 2000;
Measuring method:It is protected from light operation;This product content under content uniformity item is taken, finely ground, precision weighs (to be approximately equivalent in right amount
Dehydroretinol 0000IU, calciferol 2000IU, vitamin E 10.0mg) it sets in 100ml conical flask with cover, 25ml is added in precision
N-hexane, weighed weight are set in ice bath and are ultrasonically treated 30 minutes, take out, then weighed weight, less loss weight is supplied with n-hexane,
It shakes up, filters, precision measures subsequent filtrate 10ml, is dried up with nitrogen, and residue isopropanol dissolves and be settled to 10ml, shakes up, filter
It crosses, precision measures 10 μ l of subsequent filtrate and injects liquid chromatograph, records chromatogram;Separately take vitamine A acetate, calciferol and dimension
Raw element E reference substances are appropriate, accurately weighed, dissolve with isopropanol and quantify dilution be made in every 1ml respectively containing 0.3mg, 2 μ g and
The mixed solution of 0.5mg, product solution, is measured in the same method as a contrast.By external standard method with calculated by peak area to get.
(7) 5- hydroxyls anthranilic acid
It is measured according to high performance liquid chromatography (two annex V D of Chinese Pharmacopoeia version in 2010);
Chromatographic condition and system suitability:It is filler with octadecylsilane chemically bonded silica;It is flowing with acetonitrile
Phase A, 0.05mol/L potassium dihydrogen phosphate (containing 0.04% sodium pentanesulfonate) are Mobile phase B, and the regulation according to the form below carries out ladder
Degree elution;Flow velocity 1.0ml/min, Detection wavelength 240nm, column temperature are 25 DEG C;Number of theoretical plate presses 5- hydroxyl anthranilic acids peak
5000 should be not less than by calculating.
Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
0~10 | 0 | 100 |
10~20 | 20 | 80 |
21~30 | 0 | 100 |
Measuring method:This product content under content uniformity item is taken, finely ground, precision weighs (it is adjacent to be approximately equivalent to 5- hydroxyls in right amount
Aminobenzoic Acid 0.5mg) it sets in 25ml measuring bottles, 0.01mol/L hydrochloric acid solution about 20ml are added, is ultrasonically treated 30 minutes, lets cool, it is dilute
It releases to scale, shakes up, filter;Precision measures 10 μ l of subsequent filtrate and injects liquid chromatograph, records chromatogram;Separately take 5- hydroxyl neighbour's ammonia
Benzoic acid reference substance is appropriate, accurately weighed, makes dissolving with 0.01mol/L hydrochloric acid solutions, and quantify dilution be made in every 1ml containing about
The solution of 0.02mg, product solution, is measured in the same method as a contrast.By external standard method with calculated by peak area to get.
Each capsule being prepared as above is according to above-mentioned【Assay】Method is detected, 8 kinds of amino acid and the life of various dimensions
Element measurement result active component corresponding to capsule theoretical inventory coincide, its respectively theory inventory 95~
In 105% range.
Test example 2:The study on the stability of capsule
The capsule dispensed with gelatin hollow capsule being prepared as above is respectively placed in seal-packed aluminum-plastic composite membrane bag
In, it is placed under 40 °C of constant temperatures and places June, various amino acid and dimension life in each capsule when measuring 0 month respectively with June
The content of element.For the same amino acid or vitamin in same a collection of capsule, examination below calculates the residual of the active constituent
Remaining content (%):
Residual content (%)=(0 month content of content ÷ in June) × 100%
Above-described embodiment 1 to embodiment 12 various capsules, after measured:
Their leucine, isoleucine, lysine, methionine, valine, threonine, phenylalanine are at June
Residual content be all higher than 94%, in 94~99% ranges, comply fully with general requirements for pharmaceuticals residual content be more than 90%
Regulation;
Their vitamin A, calciferol, vitamin B1, vitamin B2, niacinamide, vitamin B6, folic acid, calcium pantothenate,
The residual content of vitamin E, 5- hydroxyls anthranilic acid at June is all higher than 93%, complete in 93~98% ranges
Meet the regulation that general requirements for pharmaceuticals residual content is more than 90% entirely;
The residual content of both the vitamin Cs of various capsules, tryptophan at June respectively in 93~97% ranges and
In 93~95% ranges.
Test example 21:
The content of ten kinds of capsules of above-described embodiment 1 to embodiment 10 is taken out from capsule shells and directly uses vial
Packing either directly uses the packing of aluminum plastic compound membrane bag or with hydroxypropyl methylcellulose Capsules (Chinese medicines quasi-word
F20090002 it) dispenses, either with algal polysaccharides Capsules (Chinese medicines quasi-word F20050002) packing or with the hollow glue of pectin
Packing (is made) in capsule according to 200910185990.X specifications 1 methods of embodiment of page 2, or with carboxymethyl cellulose Capsules
(being made according to 200910116242.6 specification, 1 methods of embodiment of page 3) packing.Ten kinds of capsules are measured according to 2 the method for test example
Agent content powder stability in this 6 kinds of inner packings being in direct contact with drug.
The results show that during whole capsule 's content powder are packed at 6 kinds
Their leucine, isoleucine, lysine, methionine, valine, threonine, phenylalanine and tryptophan
Residual content at June is all higher than 94%, and in 94~98% ranges, it is big to comply fully with general requirements for pharmaceuticals residual content
In 90% regulation;
Their vitamin A, calciferol, vitamin B1, vitamin B2, niacinamide, vitamin B6, folic acid, calcium pantothenate,
This residual content at June of vitamin E, 5- hydroxyls anthranilic acid and vitamin C is all higher than 93%, 93~
In 98% range, the regulation that general requirements for pharmaceuticals residual content is more than 90% is complied fully with;It is not present in gelatine capsule agent
The unstable situation of both the vitamin C that occurs when packaging, tryptophans.In addition after measured, made in embodiment 11 and embodiment 12
Each capsule obtained is measured according to 21 method of this test example, they are essentially identical with the result of the capsule of embodiment 1-10.
Test example 22:
Respectively refer to the formula and preparation method of embodiment 1-10, different is only not add starch and silicea, obtain 10 kinds with
The capsule of gelatin hollow capsule filling.Leucine, different bright ammonia in 10 kinds of capsules are measured referring next to the method for test example 2
Acid, lysine, methionine, valine, threonine, phenylalanine and vitamin A, calciferol, vitamin B1, dimension life
This remnants at June of plain B2, niacinamide, vitamin B6, folic acid, calcium pantothenate, vitamin E, 5- hydroxyls anthranilic acid
As a result content shows that residual content of whole components at June including tryptophan is all higher than 93%, 93~97%
In range.The residual content of tryptophan and vitamin C at June is respectively in 75~82% ranges and 83~87% ranges
It is interior.
Test example 23:
The formula and preparation method of embodiment 1-10 are respectively referred to, different is only not add starch and silicea, obtains 10 kinds and mixes
Powder is closed, respectively uses this 10 kinds of mixed-powders respectively the packing of aluminum plastic compound membrane bag, vial packing, hydroxypropyl methylcellulose empty
Heart-soothing capsule or the packing of algal polysaccharides Capsules.Ten kinds of content powder are measured in this 4 kinds and medicine according to 2 the method for test example
Stability in the inner packing that product are in direct contact.
The results show that during whole capsule 's content powder are packed at 4 kinds:
Their leucine, isoleucine, lysine, methionine, valine, threonine, phenylalanine, tryptophan
Residual content at June is all higher than 93%, and in 93~96% ranges, it is big to comply fully with general requirements for pharmaceuticals residual content
In 90% regulation;
Their vitamin A, calciferol, vitamin B1, vitamin B2, niacinamide, vitamin B6, folic acid, calcium pantothenate,
This residual content at June of vitamin E, 5- hydroxyls anthranilic acid, vitamin C is all higher than 93%, 93~
In 97% range.
As it can be seen that when not adding starch and silicea, hybrid particles are unstable in gelatin hollow capsule, and in other interior packets
It is stable to fill in material.
Test example 24:
The formula and preparation method of embodiment 1-10 are respectively referred to, different is only that vitamin C is not added in prescription, obtains 10 kinds
The capsule filled with gelatin hollow capsule.Leucine, different bright ammonia in 10 kinds of capsules are measured referring next to the method for test example 2
Acid, lysine, methionine, valine, threonine, phenylalanine and tryptophan and vitamin A, calciferol, vitamin
B1, vitamin B2, niacinamide, vitamin B6, folic acid, calcium pantothenate, vitamin E, 5- hydroxyls anthranilic acid this at June
Residual content, as a result whole components residual content at June of the display including tryptophan be all higher than 93%, 93
In~96% range.In addition after measured, each capsule obtained is surveyed according to 24 method of this test example in embodiment 11 and embodiment 12
Fixed, they are essentially identical with the result of the capsule of embodiment 1-10.
Test example 25:
The formula and preparation method of embodiment 1-10 are respectively referred to, different is only that tryptophan is not added in prescription, obtains 10 kinds
The capsule filled with gelatin hollow capsule.Leucine, different bright in 10 kinds of capsules is measured referring next to the method for test example 2
Propylhomoserin, lysine, methionine, valine, threonine, phenylalanine and vitamin A, calciferol, vitamin B1, dimension
Raw element B2, niacinamide, vitamin B6, folic acid, calcium pantothenate, vitamin E, vitamin C, 5- hydroxyls anthranilic acid this 6
As a result residual content when the moon shows that residual content of whole components at June including vitamin C is all higher than 93%,
In 93~95% ranges.In addition after measured, each capsule obtained shines this test example 25 in embodiment 11 and embodiment 12
Method measures, they are essentially identical with the result of the capsule of embodiment 1-10.
Test example 26:
Respectively refer to the formula and preparation method of embodiment 1-10, different be only the starch that will wherein use replace with lactose or
Microcrystalline cellulose or deduction are not added with starch, obtain 30 kinds of capsules filled with gelatin hollow capsule.Referring next to experiment
The method of example 2 measures leucine, isoleucine, lysine, methionine, valine, threonine, phenylpropyl alcohol in this 30 kinds of capsules
It is propylhomoserin, tryptophan and vitamin A, calciferol, vitamin B1, vitamin B2, niacinamide, vitamin B6, folic acid, general
This residual content at June of sour calcium, vitamin E, vitamin C, 5- hydroxyls anthranilic acid.The results show that in addition to color
Outside propylhomoserin and vitamin C, residual content of all other component at June is all higher than 94%, in 94~97% ranges;But
Be in this 30 kinds of capsules the residual content of tryptophan and vitamin C at June respectively in 82~86% ranges and
In 80~86% ranges.In addition after measured, each capsule obtained shines 26 method of this test example in embodiment 11 and embodiment 12
It measures, they are essentially identical with the result of the capsule of embodiment 1-10.This shows to work as without using starch or is used instead it
Its auxiliary material can not achieve the preparation performance of excellent stability when replacing.
Test example 27:
The formula and preparation method of embodiment 1-10 are respectively referred to, different is only that the silicea that will wherein use replaces with three silicic acid
Magnesium or aluminium-magnesium silicate or deduction are not added with silicea, obtain 30 kinds of capsules filled with gelatin hollow capsule.Referring next to examination
The method for testing example 2 measures leucine, isoleucine, lysine, methionine, valine, threonine, benzene in this 30 kinds of capsules
Alanine, tryptophan and vitamin A, calciferol, vitamin B1, vitamin B2, niacinamide, vitamin B6, folic acid,
This residual content at June of calcium pantothenate, vitamin E, vitamin C, 5- hydroxyls anthranilic acid.The results show that in addition to
Outside tryptophan and vitamin C, residual content of all other component at June is all higher than 93%, in 93~96% ranges;
But in this 30 kinds of capsules the residual content of tryptophan and vitamin C at June respectively in 80~83% ranges with
And 83~86% in range.This shows when without using silicea or being used instead when other auxiliary materials are replaced and can not achieve good stable
The preparation performance of property.
The above test example shows to load the compound amino acid vitamin mixed-powder filled in Capsules, with gelatin
In the case of for Capsules material there is taboo in both vitamin C and tryptophan, can overcome these by the method for the invention
Taboo.
Test example 28:Prepare capsule
The capsule for including 7 kinds of pellets is made in formula and preparation method according to CN101773512B (ten thousand Hes) embodiment 1, uses gelatin
Capsules load.According to the method above with reference to test example 2 measure leucine in this capsule, isoleucine, lysine,
Methionine, valine, threonine, phenylalanine, tryptophan and vitamin A, calciferol, vitamin B1, vitamin
B2, niacinamide, vitamin B6, folic acid, calcium pantothenate, vitamin E, vitamin C, 5- hydroxyls anthranilic acid this at June
Residual content.The results show that the residual content including tryptophan and ascorbic whole components at June is all higher than 93%,
In 93~98% ranges.Although the capsule of this prior art preparation is stable, it require that using extremely multiple
Miscellaneous production technology.
Test example 3:The hygroscopicity of capsule 's content powder is investigated
The hygroscopicity of capsule 's content powder is investigated:Capsule 's content powder is placed in vial, opposite
January is placed under the conditions of temperature 75%, 25 DEG C of temperature, is weighed to powder before and after disposition, with 1 the end of month increased weight divided by initially
The percentage of powder weight is used as weightening percentage (%), and using the weightening percentage (%) as evaluation index.
It has been measured that,
The weightening percentage (%) of whole Capsule content powder of embodiment 1-12 is in 0.3~1.9% range;
The weightening percentage (%) of 22 10 kinds of Capsule content powder of gained of test example is in 8.5~13.6% ranges
It is interior;
The weightening percentage (%) of the whole Capsule content powder of 26 gained of test example is in 7.7~13.9% ranges
It is interior;
Test example 27 does not have to the weightening percentage of the Capsule content powder (only add starch and be not added with silicea) of silicea
Number (%) is in 6.4~11.2% ranges;
The formula and preparation method of embodiment 1 and embodiment 2 are respectively referred to, different is only that the starch that will wherein use replaces with
Dextrin, sucrose, hydroxypropyl methyl cellulose, carboxymethyl starch, sodium carboxymethyl starch, methylcellulose or ethyl cellulose, obtain
To 14 kinds of capsules, the weightening percentage (%) of content powder is in 7.8~13.1% ranges.
These results indicate that in the case where preparation is directly mixed without preparing piller with powder, amino acid/dimension life
It adds starch in cellulose capsule to be advantageous for obtaining the capsule filling with agent of low hygroscopicity, but this effect needs silicon
It could be obtained in the presence of agent.
Embodiments of the present invention are not limited to the above embodiments, and that makes without departing from the purpose of the present invention is various
Within variation all belongs to the scope of protection of the present invention.
Claims (14)
1. a kind of capsule comprising capsule shells and be wrapped in the capsule shells and be in powder or granular filler;Institute
It is using gelatin as gelatin hollow capsule made of key component to state capsule shells, and the filler includes active material and medicinal auxiliary
Material;
Active material that each grain of the capsule includes and in an amount of from:
The capsule is that the directly encapsulated mode of powder is prepared;The pharmaceutic adjuvant includes:Starch and silicea, institute
It states silicea and is selected from silica, colloidal silicon dioxide, talcum powder;Amount of starch is 100~300mg in each capsule, each
Silicea accounts for the 0.2~10% of filler weight in grain capsule.
2. capsule according to claim 1, each grain includes that the amount of active material is:
3. capsule according to claim 1, each grain includes that the amount of active material is:
4. capsule according to claim 1, methionine is L-Methionine or DL- METHIONINE.
5. capsule according to claim 1, the amount of starch for including in each grain is 100~250mg.
6. capsule according to claim 1, the silicea for including in each grain accounts for the 0.5~5% of the filler weight.
7. capsule according to claim 1, the silicea for including in each grain accounts for the 0.5~3% of the filler weight.
8. capsule according to claim 1, the weight for the filler for including in each grain is 200~500mg.
9. capsule according to claim 1, the weight for the filler for including in each grain is 225~450mg.
10. capsule according to claim 1, the weight for the filler for including in each grain is 250~400mg.
11. the granularity of capsule according to claim 1, filler is:95% or more particle can be sieved by 50 mesh.
12. the granularity of capsule according to claim 1, filler is:90% or more particle can be sieved by 65 mesh.
13. according to claim 1 to 12 any one of them capsule, it is prepared by method comprising the following steps
's:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
14. the method for preparing any one of claim 1 to 12 capsule, this approach includes the following steps:
(i) each solid material is respectively crushed into the powder that can be sieved by 65 mesh;
(ii) each material is uniformly mixed, at mixed powder eventually;
(iii) mixed powder eventually is filled into hard capsule case, capsule body and capsule cap is set with, sealing to get.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610060285.7A CN105596358B (en) | 2016-01-28 | 2016-01-28 | Compound capsule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610060285.7A CN105596358B (en) | 2016-01-28 | 2016-01-28 | Compound capsule |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105596358A CN105596358A (en) | 2016-05-25 |
CN105596358B true CN105596358B (en) | 2018-07-13 |
Family
ID=55977093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610060285.7A Active CN105596358B (en) | 2016-01-28 | 2016-01-28 | Compound capsule |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105596358B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1424027A (en) * | 2002-12-25 | 2003-06-18 | 王颖 | Composite amino acid capsule and preparation thereof |
CN101773512A (en) * | 2010-01-25 | 2010-07-14 | 深圳万和制药有限公司 | 8-amino acid/11-vitamin containing micro granule capsule and preparation method thereof |
CN102784147A (en) * | 2011-05-19 | 2012-11-21 | 金色年华药业有限公司 | Compound amino acid vitamin capsule |
CN103142633A (en) * | 2013-02-22 | 2013-06-12 | 深圳万和制药有限公司 | Compound amino acid capsule including eight amino acids and eleven vitamins |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
-
2016
- 2016-01-28 CN CN201610060285.7A patent/CN105596358B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1424027A (en) * | 2002-12-25 | 2003-06-18 | 王颖 | Composite amino acid capsule and preparation thereof |
CN101773512A (en) * | 2010-01-25 | 2010-07-14 | 深圳万和制药有限公司 | 8-amino acid/11-vitamin containing micro granule capsule and preparation method thereof |
CN102784147A (en) * | 2011-05-19 | 2012-11-21 | 金色年华药业有限公司 | Compound amino acid vitamin capsule |
CN103142633A (en) * | 2013-02-22 | 2013-06-12 | 深圳万和制药有限公司 | Compound amino acid capsule including eight amino acids and eleven vitamins |
Also Published As
Publication number | Publication date |
---|---|
CN105596358A (en) | 2016-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102824362B (en) | Medicine composition of oral rehydration salt | |
CN101411710B (en) | Pemetrexed disodium freeze-dried injection and preparation method thereof | |
Silva et al. | Preparation of extemporaneous oral liquid in the hospital pharmacy | |
CN101522185B (en) | Antidepressant agent | |
CN105663107B (en) | Compound amino acid capsule agent | |
CN105596358B (en) | Compound capsule | |
CN102335114B (en) | Stable ibuprofen arginine injection and preparation method thereof | |
CN115919896B (en) | Trace element composition, preparation method and application thereof | |
MacHeras et al. | Studies on freeze‐dried drug‐milk formulations II: Effect of regenerated fluid volume on nitrofurantoin bioavailability | |
CN103768088B (en) | Pharmaceutical composition containing water-soluble vitamins for injection, fat-soluble vitamins for injection and medium/long-chain fat emulsion injection | |
CN107028912B (en) | A kind of preparation method of Irbesartan Capsules | |
CN107184548B (en) | A kind of highly-safe L-ornidazole injection liquid and preparation method thereof | |
CN115969778A (en) | Sulpiride injection for treating mental diseases and preparation method and application thereof | |
CN103462887A (en) | Vitamin K1 injection and preparation method thereof | |
CN103860461A (en) | Medicinal composition containing active component ambroxol hydrochloride | |
CN106860446A (en) | Pediatric compound amino acid injection 19AA I compositions and the method for reducing its oxygen content | |
CN102988281A (en) | Injection of ambroxol hydrochloride and preparation method thereof | |
CN102552210B (en) | Entecavir capsule and preparation method thereof | |
CN105726503A (en) | Levofloxacin hydrochloride tablet | |
Hadi et al. | Impact of capsules as a carrier for multiple unit drug delivery and the importance of HPMC capsules | |
CN103893767A (en) | Ibuprofen medicine composition with stable quality | |
CN102319259B (en) | 5% glucose adult nutrient solution and preparation method thereof | |
CN107737099B (en) | A kind of highly-safe L-ornidazole injection liquid and preparation method thereof | |
CN102824340A (en) | Ibuprofen composition injection and preparation method thereof | |
CN107224429B (en) | A kind of highly-safe L-ornidazole injection liquid and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |